GLENMARKGlenmark Pharmaceuticals Limited
Convert to ideaPharmaceuticals & Biotechnology · Pharmaceuticals · India Ratings: AA+ (Stable)
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeDown 5.6 this quarter.
Momentum from moving averages, Supertrend and RSI.
4 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
4 found · risk elevated
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹4157 Cr | ₹264 Cr | 14.27% | 6.35% | ₹9.35 | 6.3x |
| Q1 FY2027 | ₹4018 Cr | ₹483 Cr | 15.72% | 12.01% | ₹17.11 | 12.9x |
| Q4 FY2026 | ₹3771 Cr | ₹301 Cr | 16.30% | 7.99% | ₹10.68 | 10.1x |
| Q3 FY2026 | ₹3901 Cr | ₹403 Cr | 18.34% | 10.34% | ₹14.29 | 13.9x |
| Q2 FY2026 | ₹6047 Cr | ₹610 Cr | 36.69% | 10.09% | ₹21.63 | 15.6x |
| Q1 FY2026 | ₹3264 Cr | ₹47 Cr | 13.80% | 1.44% | ₹1.66 | 2.6x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 TREAT trispecific T cell engager, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 2301, a NK cell engager that is in preclinical trial for solid tumors; and GRC 65327, a Cbl-b inhibitor small molecule for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of hidradenitis suppurativa; and ISB 830-X8, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.